Press release – 09.10.2017

Theraclion Announces Exclusive Distribution Agreement with EDAP TMS France


EDAP France to Market Echotherapy for ablation of breast fibroadenomas and benign thyroid nodules

THERACLION today announced the signature of an Agreement with EDAP TMS SA, to exclusively distribute Theraclion’s Echopulse® system in France. Originated as a spin-off from EDAP, the global leader in therapeutic ultrasound specialized in urology, Theraclion has developed echotherapy in the use of two indications, fibroadenoma of the breast and benign thyroid nodules and successfully expanded its commercialization efforts in Europe and Asia with key markets being Germany and Hong-Kong. The companies have partnered closely for years and their commercial teams address the same clinics and hospitals.


Read the press release

Print Friendly, PDF & Email